Transplant Infectious Disease

Article	Citations
Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients	81
Threatening drug‐drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID‐19)	51
Mucormycosis associated with COVID‐19 in two kidney transplant patients	49
Outcomes of COVID‐19 in solid organ transplant recipients: A matched cohort study	42
Treatment of recurrent urinary tract infections in a 60‐year‐old kidney transplant recipient. The use of phage therapy	42
Organ recovery from deceased donors with prior COVID‐19: A case series	40
COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul	39
Case report: A kidney transplant patient with mild COVID‐19	39
COVID‐19 in solid organ transplant recipients: Dynamics of disease progression and inflammatory markers in ICU and non‐ICU admitted patients	39
COVID‐19 in solid organ transplant recipients: No difference in survival compared to general population	37
Viruses, friends, and foes: The case of Torque Teno Virus and the net state of immunosuppression	36
COVID‐19 in lung transplant recipients	35
Treatment of immunocompromised COVID‐19 patients with convalescent plasma	34
Monoclonal antibody treatment for COVID‐19 in solid organ transplant recipients	33
Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients	33
COVID‐19 in recent heart transplant recipients: Clinicopathologic features and early outcomes	33
COVID‐19 pneumonia in kidney transplant recipients: Focus on immunosuppression management	31
COVID‐19 in an HIV‐positive kidney transplant recipient	30
Mucormycosis in post‐COVID‐19 renal transplant patients: A lethal complication in follow‐up	30
Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real‐world evidence	30
Case series of six kidney transplanted patients with COVID‐19 pneumonia treated with tocilizumab	29
SARS‐CoV2 and immunosuppression: A double‐edged sword	29
Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis	28
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch	27
An International survey on living kidney donation and transplant practices during the COVID‐19 pandemic	26

The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation	25
Outcome of COVID‐19 in liver transplant recipients: A preliminary report from Northwestern Italy	25
The pandemic provides a pathway: What we know and what we need to know about using COVID positive donors	24
Iranian kidney transplant recipients with COVID‐19 infection: Clinical outcomes and cytomegalovirus coinfection	24
Antibody response to two doses of inactivated SARS‐CoV‐2 vaccine (CoronaVac) in kidney transplant recipients	24
Outpatient management of kidney transplant recipients with suspected COVID‐19—Single‐center experience during the New York City surge	24
A case of successful treatment of severe COVID‐19 pneumonia with favipiravir and tocilizumab in post–kidney transplant recipient	24
Successful recovery from severe COVID‐19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab	24
Feasibility and safety of remdesivir in SARS‐CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation	23
Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy	22
Hepatitis C‐positive donor to negative recipient kidney transplantation: A real‐world experience	22
Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature	22
Invasive pulmonary aspergillosis associated with COVID‐19 in a kidney transplant recipient	21
Humoral and cellular immune responses to the SARS‐CoV‐2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls	21
SARS‐CoV‐2 infection in kidney transplant recipients: Experience of the italian marche region	21
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction	21
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients	21
COVID‐19 and kidney transplant recipients	21
Treatment of invasive IMP‐4Enterobacter cloacaeinfection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review	20
Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients	20
Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib	20
Kidney transplantation from a SARS‐CoV‐2‐positive donor for the recipients with immunity after COVID‐19	19
Successful liver transplantation in a patient recovered from COVID‐19	19
Breakthrough COVID‐19 after SARS‐CoV‐2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy	19
COVID‐19 and liver transplantation: Lessons learned from three reported cases	19
Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection	18
Short‐term liver transplant outcomes from SARS‐CoV‐2 lower respiratory tract NAT positive donors	18
Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients	18
Successful heart and kidney transplantation from a deceased donor with PCR positive COVID‐19	18
Is the Omicron variant truly less virulent in solid organ transplant recipients?	18
COVID‐19 in lung transplant recipients: A case series from Milan, Italy	18
Interleukin‐6 receptor antagonist therapy to treat SARS‐CoV‐2 driven inflammatory syndrome in a kidney transplant recipient	18
Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation?	17
Varied clinical presentation and outcome of SARS‐CoV‐2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain	17
Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee	17
Successful recovery from COVID‐19 in three kidney transplant recipients who received convalescent plasma therapy	17
Humoral and cellular response of COVID‐19 vaccine among solid organ transplant recipients: A systematic review and meta‐analysis	17
Early experience with SARs‐CoV‐2 mRNA vaccine breakthrough among kidney transplant recipients	17
Impact of donor multidrug‐resistant organisms on solid organ transplant recipient outcomes	17
COVID‐19 pneumonia in kidney transplant recipients—Where we are?	17
COVID‐19 infection in solid organ transplant recipients: A single‐center experience with patients immediately after transplantation	16
COVID‐19 clinical manifestations and treatment strategies among solid‐organ recipients: A systematic review of cases	16
Antifungal prophylaxis in lung transplant recipients: A systematic review and meta‐analysis	16
Zoonotic sporotrichosis in renal transplant recipients from Rio de Janeiro, Brazil	16
Commercial insurance delays direct‐acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients	16
A case report of successful kidney transplantation from a deceased donor with terminal COVID‐19‐related lung damage: Ongoing dilemma between discarding and accepting organs in COVID‐19 era!	16
Failed antibody response in a renal transplant recipient with SARS‐CoV‐2 infected	15
Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard	15
Effect of immunosuppression maintenance in solid organ transplant recipients with COVID‐19: Systematic review and meta‐analysis	15
A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients	15

Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center	15
Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021	14
Influence of immunosuppression on seroconversion against SARS‐CoV‐2 in two kidney transplant recipients	14
Clinical characteristics of COVID‐19 in solid organ transplant recipients following COVID‐19 vaccination: A multicenter case series	14
Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India	14
Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation	14
American trypanosomiasis (Chagas disease) in solid organ transplantation	14
Pregnancy after CMV infection following uterus transplantation: A case report from the Dallas Uterus Transplant Study	14
Cell‐free next‐generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study	14
Eosinophilic gastroenteritis and graft‐versus‐host disease induced by transmission of Norovirus with fecal microbiota transplant	14
Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database	14
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single‐center experience	14
Coronavirus disease 2019 in renal transplant recipients: Report of two cases	13
Coinfection rates and clinical outcome data for cytomegalovirus and Epstein‐Barr virus in post‐transplant patients: A systematic review of the literature	13
Liver transplant recipients infected with SARS‐CoV‐2 in the early postoperative period: Lessons from a single center in the epicenter of the pandemic	13
COVID‐19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression	13
Post‐infection pulmonary sequelae after COVID‐19 among patients with lung transplantation	13
Evaluation of Quantiferon®‐Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients	13
Heart and liver transplant recipients from donor with positive SARS‐CoV‐2 RT‐PCR at time of transplantation	13
Kidney transplantation during coronavirus 2019 pandemic at a large hospital in Miami	12
Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers	12
Simultaneous coccidioidomycosis and phaeohyphomycosis in a kidney transplant recipient: A case report and literature review	12
Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the	12
Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus	12
Scedosporium apiospermum and Lomentospora prolificans in lung transplant patients – A single center experience over 24 years	12
The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients	12
Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: A matched case‐control study	12
Is it safe to perform abdominal transplantation from SARS‐CoV‐2 polymerase chain reaction positive donors?	12
The role of 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in assessment of complex invasive fungal disease and opportunistic co‐infections in patients with acute	11
Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans	11
Kidney transplant recipients infected by COVID‐19: Review of the initial published experience	11
Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5‐year analysis within the Swiss Transplant Cohort study	11
Antifungal stewardship in solid organ transplantation	11
Immune reconstitution and severity of COVID‐19 among hematopoietic cell transplant recipients	11
The outcomes of Clostridioides difficile infection in inpatient liver transplant population	11
Recent developments in trichodysplasia spinulosa disease	11
Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients	11
T‐cell adoptive immunotherapy for BK nephropathy in renal transplantation	11
Polymyxin B‐induced skin hyperpigmentation	11
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease	11
Successful treatment of Aspergillus fumigatus sternal osteomyelitis with isavuconazole in a heart transplant recipient	11
Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity	11
Hyperammonemia syndrome due to Ureaplasma infection after liver‐kidney transplant	11
Sources and prevention of graft infection during long‐term ex situ liver perfusion	11
Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients	10
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study	10
Rapid molecular detection of airway pathogens in lung transplant recipients	10
Short‐term kidney transplant outcomes from severe acute respiratory syndrome coronavirus 2 lower respiratory tract positive donors	10
Kidney transplant recipients’ attitudes toward COVID‐19 vaccination and barriers and enablers to vaccine acceptance	10
A randomized, controlled trial comparing the immunogenecity and safety of a 23‐valent pneumococcal polysaccharide vaccination to a repeated dose 13‐valent pneumococcal conjugate vaccination in kidney	10
The importance of uninterrupted albendazole treatment in patients with unresectable alveolar echinococcosis undergoing liver transplantation	10
Incidence of herpes zoster in adult solid organ transplant recipients: A meta‐analysis and comprehensive review	10
Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients	10
Clinical characteristics and outcome of COVID‐19 pneumonia in kidney transplant recipients in Razi hospital, Rasht, Iran	10
Prediction of cytomegalovirus infection: A single‐center experience utilizing a newly available cell‐mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstr	10
SARS‐CoV‐2 infection in kidney transplant recipients: Early report of five cases	9
Antibody response to mRNA SARS‐CoV‐2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation	9
Incidence, etiology, risk factors, and outcomes of pre‐engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation	9
Isolated pulmonary fusariosis caused by Neocosmospora pseudensiformis in a liver transplant recipient: A case report and review of the literature	9
COVID‐19 in pancreas transplant recipients	9
Hyponatremia: A possible immuno‐neuroendocrine interface with COVID‐19 in a kidney transplant recipient	9
Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID‐19	9
A pragmatic outreach pilot to understand and overcome barriers to COVID‐19 vaccination in abdominal organ transplant	9
Universal molecular Clostridioides difficile screening and overtreatment in solid organ transplant recipients	9
Bronchial anastomosis dehiscence and stenosis caused by donor‐transmitted Mycoplasma hominis infection in a lung transplant recipient: Case report and literature review	9
Infectious disease consultation is effective in boosting vaccine coverage in patients awaiting kidney transplantation: A French prospective study	9
Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?	9
Recurrent nocardiosis in solid organ transplant recipients: An evaluation of secondary prophylaxis	9
Successful management of noncirrhotic hyperammonemia syndrome after kidney transplantation from putative Ureaplasma infection	9
Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: A controlled clinical trial	9
Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation	9
Matched retrospective study of infective endocarditis among solid organ transplant recipients compared to non‐transplant: Seven‐year experience in a US Referral Center	9
Diagnosis of central nervous system invasive aspergillosis in a liver transplant recipient using microbial cell‐free next generation DNA sequencing	9
Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single‐center descriptive experience	9
De novo emergence of SARS‐CoV‐2 spike mutations in immunosuppressed patients	9
The coverage of influenza and pneumococcal vaccination among kidney transplant recipients and waiting list patients: A cross‐sectional survey in Denmark	9
Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States	9
Post‐transplant survey to assess patient experiences with donor‐derived HCV infection	9
Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection	9
Hyperammonemia syndrome due to Ureaplasma urealyticum in a kidney transplant recipient: A case of disseminated disease from a fluoroquinolone‐resistant isolate	9

SARS‐CoV‐2 infection after two doses of mRNA vaccine in renal transplant recipients	9
Epidemiology, management, and graft outcomes after West Nile virus encephalitis in kidney transplant recipients	9
Reinfection with SARS‐CoV‐2 in solid‐organ transplant recipients: Incidence density and convalescent immunity prior to reinfection	9
Donor derived hepatitis B virus infection: Analysis of the Organ Procurement & Transplantation Network/United Network for Organ Sharing Ad Hoc Disease Transmission Advisory Committee	8
Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation	8
Moving xenotransplantation from bench to bedside: Managing infectious risk	8
Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients	8
Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis	8
Early steps to kidney transplantation among persons with HIV and end‐stage renal disease in ESRD network 6	8
Incidental COVID‐19 in a heart‐kidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS‐CoV‐2 immune response	8
The hamletic dilemma of patients waiting for kidney transplantation during the COVID‐19 pandemic: To accept or not to accept (an organ offer)?	8
Cytomegalovirus antiviral stewardship in the COVID‐19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies	8
Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?	8
Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: A case report	8
Perinephric abscess in a renal transplant recipient due to Mycoplasma hominis: Case report and review of the literature	8
Efficacy of β‐lactam/β‐lactamase inhibitors to treat extended‐spectrum beta‐lactamase‐producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients	8
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir	8
Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis	8
Daptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients	8
Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients	8
COVID‐19 in lung transplant recipients: A single‐center experience	8
A case series of multidrug‐resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country	8
Donor‐derived tuberculosis among solid organ transplant recipients in the United States—2008 to 2018	7
Incidence rate of active tuberculosis in solid organ transplant recipients: Data from a nationwide population cohort in a high‐endemic country	7
Successful implementation of preventive measures leads to low relevance of SARS‐CoV‐2 in liver transplant patients: Observations from a German outpatient department	7
Effectiveness of short vs long‐course perioperative antibiotics in lung transplant recipients with donor positive respiratory cultures	7
Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE‐IT* study	7
Cytomegalovirus myocarditis in solid organ transplant recipients: A case series and review of literature	7
Heart transplant recipient patient with COVID‐19 treated with tocilizumab	7
COVID‐19 vaccination timing and kidney transplant waitlist management: An international perspective	7
Gram‐negative bacteremia in solid organ transplant recipients: Clinical characteristics and outcomes as compared to immunocompetent non‐transplant recipients	7
Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation	7
Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance	7
JC virus‐associated nephropathy in a post‐heart and ‐kidney transplantation patient	7
Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR)	7
Trichodysplasia spinulosa: Case reports and review of literature	7
Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report	7
Retrospective case analysis of antiviral therapies for HHV‐6 encephalitis after hematopoietic stem cell transplantation	7
Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation	7
Antibiotic allergy labels in immunocompromised populations	7
Clearance of longstanding treatment‐resistant warts during COVID‐19 in a transplant recipient	7
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole	7
Trimethoprim/sulfamethoxazole for nocardiosis in solid organ transplant recipients: Real‐life data from a multicentre retrospective study	7
SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps	7
Management of transplant patients outside hospital during COVID‐19 epidemic: A Chinese experience	7
Development and longevity of antibodies against SARS‐CoV‐2 in kidney transplant recipients after symptomatic COVID‐19	7
COVID‐19, liver transplant, and immunosuppression: Allies or foes?	7
Moderate acceptance of COVID‐19 vaccination in patients pre‐ and post‐heart transplantation: Experiences from a German Transplant Centre	7
Bacterial genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus bacteremia	7
Favorable outcomes of COVID‐19 in vaccinated hematopoietic stem cell transplant recipients: A single‐center experience	7
Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta‐analysis	7
Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (C	7
The burden of cytomegalovirus infection remains high in high‐risk kidney transplant recipients despite six‐month valganciclovir prophylaxis	7
Are Clostridioides difficile infections being overdiagnosed in hematopoietic stem cell transplant recipients?	7
Risk factors and clinical outcomes of tuberculosis among kidney transplant recipients in high endemic country	7
Impact of SARS‐CoV‐2 outbreak on heart and lung transplant: A patient‐perspective survey	6
Hypothermic oxygenated machine‐perfusion fluid‐related infection in a liver transplant recipient: First case report in the literature	6
Association between gut colonization of vancomycin‐resistant enterococci and liver transplant outcomes	6
Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review	6
Lung transplant recipient attitudes and beliefs on accepting an organ that is positive for hepatitis C virus	6
Central nervous system infections in renal transplant recipients	6
Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis	6
Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post‐engraftment p	6
Secondary syphilis with liver involvement in a liver transplant recipient	6
Standardization of post‐operative antimicrobials reduced exposure while maintaining good outcomes in pediatric liver transplant recipients	6
Hyperammonemia syndrome post‐lung transplantation: Case series and systematic review of literature	6
Hepatitis B Immunoglobulin discontinuation in long‐term liver transplant patients	6
Liver transplant evaluation for fulminant liver failure due to acute hepatitis A infection: Case series and literature review	6
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review	6
Talaromycosis in a renal transplant recipient returning from South China	6
Successful management of T‐cell mediated rejection in a recent kidney transplant recipient with COVID‐19 associated severe acute respiratory syndrome	6
Transmission of malaria from donors to solid organ transplant recipients: A case report and literature review	6
Live virus vaccination of pediatric solid organ transplant candidates within 1 month prior to transplantation: A multicenter experience	6
Ecthyma gangrenosum without bacteremia in a 54‐year‐old woman with heart transplant	6
Inherited chromosomally integrated human herpesvirus‐6 in a patient with XIAP deficiency	6
Kinetics of torquetenovirus DNA load in a recent kidney transplant recipient with mild SARS‐CoV‐2 infection and a failed antibody response	6
Risks and outcomes of adenovirus disease in pediatric hematopoietic stem cell transplant recipients—Comparison of current antiviral treatment options	6
Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study	6
Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study	6
A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?	6
Blastomycosis in solid organ transplant recipients—A retrospective series from southeastern Wisconsin	6
A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high‐risk patients and a pre‐emptive strategy in intermediate‐risk patients: Combining the bes	6
Failure of multiplex meningitis/encephalitis (ME) NAT during cryptococcal meningitis in solid organ recipients	6
Post kidney transplant histoplasmosis: An under‐recognized diagnosis in India	6
Clinical course of human monkeypox infection in a renal transplant recipient living with human immunodeficiency virus	6
Donor‐derived herpes simplex virus hepatitis in a kidney transplant recipient and review of the literature	6
Alternative pneumocystis prophylaxis in solid organ transplant recipients at two large transplant centers	6
Disparities in vaccination rates in solid organ transplant patients	6
A nosocomial scabies outbreak originating from immunocompromised transplant patients in Turkey: Upholstery as a possible cause	6
Pyogenic liver abscess in liver transplant recipient: A warning signal for the risk of recurrence and retransplantation	6
Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients	6
Fluoroquinolones for BK viral complication after transplantation: Meta‐analysis	6
Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients	5
Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft‐versus‐host disease	5
Cutaneous infection caused by paraconiothyrium cyclothyrioides in a renal transplant recipient	5